MedTrace Logo

A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

NCT04869228 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2023-08-18

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease

Conditions

Interventions

DRUG

GT0918 tablets or placebo

GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals

Sponsors & Collaborators

  • Suzhou Kintor Pharmaceutical Inc,

    lead INDUSTRY

Principal Investigators

  • Cristhieni Rodrigues · Hospital Santa Paula

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-04
Primary Completion
2022-09-02
Completion
2023-08-02

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869228 on ClinicalTrials.gov